Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.

"Conflict of interest statement Repligen Corporation has acquired a license from Scripps Research Institute for the development of the pimelic o-aminobenzamide HDAC inhibitors first synthesized in the lab of JMG. Repligen filed for patenting of the molecules described in this manuscript. GB, SJ and JRR are employees of Repligen and JMG is a consultant for Repligen. This corporate involvement does not alter the authors' adherence to all of this journal's policies on sharing data and materials."

"We thank Steve Pash for assistance with animal husbandry, Mark Cooper (Royal Free Hospital, UCL, London) for assistance with aconitase assays and Lorraine Lawrence (Imperial College London) for assistance with histology. This work was supported by Repligen Corporation, Muscular Dystrophy Association (MDA) USA, Ataxia UK, Friedreich's Ataxia Research Alliance (FARA), GoFAR, and the Wellcome Trust [089757]."